Clinical Trial Update: Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098) [Phase 1]

View source ↗

Summary

Phase I study of MK-0683 in combination with bortezomib in multiple myeloma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Bortezomib (bortezomib)
• MK-0683

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Multiple Myeloma | Phase 1 | Status: COMPLETED | Results posted: 2021-04-09